Shots:

• The P-IIb study involves assessing of M72/AS01_E vs PBO in 3-573 adults in a ratio (1:1) to prevent Mycobacterium tuberculosis infection from developing pulmonary tuberculosis disease in tuberculosis-endemic regions across 11 sites in Kenya- South Africa and Zambia
• The P-IIb study results demonstrated a reduction in the incidence of pulmonary TB in HIV-negative adults with latent TB infection with an overall efficacy of 50% for three yrs. following vaccination- acceptable safety- and reactogenicity
• M72/AS01_E contains the M72 recombinant fusion protein- derived from two Mycobacterium tuberculosis antigens (Mtb32A and Mtb39A) combining with its Adjuvant System AS01- providing protection against TB

Click here to­ read full press release/ article 

Ref: GSK | Image: GSK